Primary effusion lymphoma (PEL) caused by Kaposi’s sarcoma-associated herpesvirus (also known as human herpesvirus-8) shows serious lymphomatous effusion in body cavities. PEL is difficult to treat and there is no standard treatment strategy. Hippuristanol is extracted from Okinawan coral Isis hippuris, and inhibits translational initiation by blocking eukaryotic initiation factor 4A, an ATP-dependent RNA helicase, binding to mRNA. Recently, there has been much interest in targeting translation initiation as an anticancer therapy. Here, we show that treatment of PEL cell lines with hippuristanol resulted in cell cycle arrest at G 1 phase, and induced caspases activation and apoptosis. Hippuristanol also reduced the expression of cyclin D2, CDK2, CDK4, CDK6 and prosurvival XIAP and Mcl-1 proteins. Activation of activator protein-1, signal transducers and activators of transcription protein 3 and Akt pathways plays a critical role in the survival and growth of PEL cells. Hippuristanol suppressed the activities of these three pathways by inhibiting the expression of JunB, JunD, c-Fos, signal transducers and activators of transcription protein 3 and Akt proteins. In a xenograft mouse model that showed ascites and diffused organ invasion of PEL cells, treatment with hippuristanol significantly inhibited the growth and invasion of PEL cells compared with untreated mice. The results of the in vitro and in vivo experiments underline the potential usefulness of hippuristanol in the treatment of PEL.
Yamamoto, K.; Ishikawa, C.; Katano, H.; Yasumoto, T.; Mori, N. Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett. 2011, 300, 225–234, doi:10.1016/j.canlet.2010.10.016.
[8]
Wen, K.W.; Damania, B. Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis. Cancer Lett. 2010, 289, 140–150, doi:10.1016/j.canlet.2009.07.004.
[9]
Bordeleau, M.-E.; Mori, A.; Oberer, M.; Lindqvist, L.; Chard, L.S.; Higa, T.; Belsham, G.J.; Wagner, G.; Tanaka, J.; Pelletier, J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2006, 2, 213–220, doi:10.1038/nchembio776.
[10]
Lindqvist, L.; Pelletier, J. Inhibitors of translation initiation as cancer therapeutics. Future Med. Chem. 2009, 1, 1709–1722, doi:10.4155/fmc.09.122.
[11]
Tsumuraya, T.; Ishikawa, C.; Machijima, Y.; Nakachi, S.; Senba, M.; Tanaka, J.; Mori, N. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem. Pharmacol. 2011, 81, 713–722, doi:10.1016/j.bcp.2010.12.025.
[12]
Zhang, C.; Ao, Z.; Seth, A.; Schlossman, S.F. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J. Immunol. 1996, 157, 3980–3987.
[13]
Tewari, M.; Quan, L.T.; O’Rourke, K.; Desnoyers, S.; Zeng, Z.; Beidler, D.R.; Poirier, G.G.; Salvesen, G.S.; Dixit, V.M. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995, 81, 801–809, doi:10.1016/0092-8674(95)90541-3.
[14]
An, J.; Sun, Y.; Rettig, M.B. Transcriptional coactivation of c-Jun by KSHV-encoded LANA. Blood 2004, 103, 222–228, doi:10.1182/blood-2003-05-1538.
[15]
Chakraborty, A.; Koldobskiy, M.A.; Bello, N.T.; Maxwell, M.; Potter, J.J.; Juluri, K.R.; Maag, D.; Kim, S.; Huang, A.S.; Dailey, M.J.; et al. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell 2010, 143, 897–910, doi:10.1016/j.cell.2010.11.032.
[16]
Casamayor, A.; Morrice, N.A.; Alessi, D.R. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: Identification of five sites of phosphorylation in vivo. Biochem. J. 1999, 342, 287–292, doi:10.1042/0264-6021:3420287.
[17]
Michai, M.; Goto, H.; Hattori, S.; Vaeteewoottacharn, K.; Wongkham, C.; Wongkham, S.; Okada, S. Soluble CD30: A possible serum tumor marker for primary effusion lymphoma. Asian Pacific J. Cancer Prev. 2012, 13, 4939–4941, doi:10.7314/APJCP.2012.13.10.4939.
[18]
Brooks, A.R.; Shiffman, D.; Chan, C.S.; Brooks, E.E.; Milner, P.G. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J. Biol. Chem. 1996, 271, 9090–9099.
[19]
Fukada, T.; Ohtani, T.; Yoshida, Y.; Shirogane, T.; Nishida, K.; Nakajima, K.; Hibi, M.; Hirano, T. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998, 17, 6670–6677, doi:10.1093/emboj/17.22.6670.
[20]
Wang, X.H.; Liu, B.R.; Qu, B.; Xing, H.; Gao, S.L.; Yin, J.M.; Wang, X.F.; Cheng, Y.Q. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: Potential uses for gene therapy. Neoplasma 2011, 58, 158–171, doi:10.4149/neo_2011_02_158.
[21]
Dan, H.C.; Sun, M.; Kaneko, S.; Feldman, R.I.; Nicosia, S.V.; Wang, H.G.; Tsang, B.K.; Cheng, J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 2004, 279, 5405–5412.
[22]
Epling-Burnette, P.K.; Liu, J.H.; Catlett-Falcone, R.; Turkson, J.; Oshiro, M.; Kothapalli, R.; Li, Y.; Wang, J.-M.; Yang-Yen, H.-F.; Karras, J.; et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 2001, 107, 351–362, doi:10.1172/JCI9940.
[23]
Chan, G.; Nogalski, M.T.; Bentz, G.L.; Smith, M.S.; Parmater, A.; Yurochko, A.D. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J. Immunol. 2010, 184, 3213–3222.
[24]
Alvarez, J.V.; Febbo, P.G.; Ramaswamy, S.; Loda, M.; Richardson, A.; Frank, D.A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005, 65, 5054–5062, doi:10.1158/0008-5472.CAN-04-4281.
[25]
Renne, R.; Zhong, W.; Herndier, B.; McGrath, M.; Abbey, N.; Kedes, D.; Ganem, D. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 1996, 2, 342–346, doi:10.1038/nm0396-342.
[26]
Katano, H.; Hoshino, Y.; Morishita, Y.; Nakamura, T.; Satoh, H.; Iwamoto, A.; Herndier, B.; Mori, S. Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J. Med. Virol. 1999, 58, 394–401, doi:10.1002/(SICI)1096-9071(199908)58:4<394::AID-JMV12>3.0.CO;2-H.
[27]
Antalis, T.M.; Godbolt, D. Isolation of intact nuclei from hematopoietic cell types. Nucl. Acids Res. 1991, 19, 4301, doi:10.1093/nar/19.15.4301.
[28]
Mori, N.; Prager, D. Transactivation of the interleukin-1α promoter by human T cell leukemia virus type I and type II Tax proteins. Blood 1996, 87, 3410–3417.
